BridgeMD
New treatment option for Kidney Neoplasms
Official title Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
ClinicalTrials.gov ID: NCT05218811
What this study is testing
- What it's testing
- Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 65
You may be able to join if
- Patients with ages between 45-90-year-old.
- Renal tumor ≤ 7 cm in the greatest extension, \>50% exophitic.
You likely can't join if
- Prior renal surgery
- M1 Disease
The study team makes the final eligibility decision.
Where it's taking place
- Miami Lakes, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Miami Lakes, Florida, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.